Archive
dermapharm holding se
Corporate News
April 13, 2021 | Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures
Corporate news
to the archive
Dermapharm forecasts exceptionally strong growth for 2021 and confirms preliminary figures
Revenue and earnings up due to organic growth and successful acquisitions
Vaccine production to commence in May 2021 ...
February 12, 2021 | Dermapharm Holding SE expands capacity to produce COVID-19 vaccine and plans for vaccine manufacturing to contribute high double-digit million € in sales in 2021
Corporate news
to the archive
Dermapharm Holding SE expands capacity to produce COVID-19 vaccine and plans for vaccine manufacturing to contribute high double-digit million € in sales in 2021
Grünwald, February 12, 2021 - Dermapharm Holding ...
November 16, 2020 | Dermapharm Holding SE continues on its growth course in third quarter of 2020
Corporate news
to the archive
Dermapharm Holding SE continues on its growth course in third quarter of 2020
Group revenue rose by 11.5% to EUR 577.2 million
Adjusted Group EBITDA increased by 4.4% to EUR 139.0 million; corresponding ...
September 10, 2020 | Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE on the production of a COVID-19 vaccine
Corporate news
to the archive
Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE on the production of a COVID-19 vaccine
Grünwald, September 10, 2020 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer ...
9 September 2020 | Dermapharm publishes Half-Year Financial Report 2020 and confirms growth course despite corona pandemic
Corporate News
back to archive
Dermapharm publishes Half-Year Financial Report 2020 and confirms growth course despite corona pandemic
Group revenue up 14% year-on-year to EUR 378 million
Adjusted EBITDA of EUR 92 million around 2% ...
August 21, 2020 | Dermapharm remains on growth course despite corona pandemic in the first half of 2020
Corporate news
to the archive
Dermapharm remains on growth course despite corona pandemic in the first half of 2020
Group revenue up 14% year-on-year to EUR 378 million
Adjusted EBITDA of EUR 92 million around 2% above previous year’s ...
June 17, 2020 | Dermapharm Holding SE: Annual General Meeting approves dividend payout of EUR 0.80 per share
Corporate news
to the archive
Dermapharm Holding SE: Annual General Meeting approves dividend payout of EUR 0.80 per share
Annual General Meeting successfully held virtually
Management Board and Supervisory Board discharged by a large ...
May 19, 2020 | Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic
Corporate news
to the archive
Dermapharm Holding SE: Growth in the first quarter of 2020 despite the corona pandemic
Group revenues increased by 17.7% to EUR 192.5 million
Adjusted Group EBITDA rose by 13.0% to EUR ...
April 8, 2020 | Dermapharm confirms profitable growth in 2019 and presents positive outlook for 2020 despite corona
Corporate news
to the archive
Dermapharm confirms profitable growth in 2019 and presents positive outlook for 2020 despite corona
Significant revenue and earnings growth in 2019 resulted from continuous product development, ...
March 31, 2020 | Dermapharm successfully acquires Allergopharma
Corporate news
to the archive
Dermapharm successfully acquires Allergopharma
Grünwald, March 31, 2020 - Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected ...
March 25, 2020 | Dermapharm continues its profitable growth in 2019
Corporate news
to the archive
Dermapharm continues its profitable growth in 2019
» Group revenue of EUR 701 million in 2019, around 23% higher than in the previous year
» Adjusted EBITDA increases by approx. 24% ...
February, 5 2020 | Dermapharm opens new logistics center in Brehna
Grünwald, February 05, 2020 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, opened the new logistics center of its subsidiary mibe GmbH Arzneimittel in Brehna near Leipzig at the turn of the year.
19 November 2019 | Dermapharm Holding SE continues to drive the company’s growth in the third quarter of 2019
Grünwald, 20 November 2019 – Dermapharm Holding SE (“Dermapharm”), a leading producer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its figures for the first nine months of 2019 today.
September 12, 2019 | Dermapharm confirms profitable growth in first half of 2019
Grünwald, 12 September 2019 ‒ Dermapharm Holding SE (“Dermapharm”), a leading producer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its half-year financial report for the first six months of 2019 today.
August 23, 2019 | Dermapharm continues on its profitable growth course in first half of 2019
Corporate news
to the archive
Dermapharm continues on its profitable growth course in first half of 2019
Revenue up 19% year-on-year to EUR 333 million
Adjusted EBITDA of EUR 90 million around 27% above previous ...
July 29, 2019 | Dermapharm Holding SE: Dr. Jürgen Ott named new CMO
Grünwald, July 29, 2019 – The Supervisory Board of Dermapharm Holding SE (“Dermapharm”) has announced a change in the composition of the Management Board. The current Chief Marketing Officer Stefan Grieving will be leaving the company for health reasons on July 31, 2019. Dr. Jürgen Ott to succeed him as of October 1, 2019.
01. Juli 2019 | Dermapharm Holding SE with increased free float
Grünwald, July 1, 2019 – Dermapharm Holding SE ("Dermapharm"), a leading manufacturer of patent-free branded drugs for selected therapeutic areas in Germany with a growing international presence, has been informed by Themis Beteiligungs-Aktiengesellschaft ("Themis") that on June 28, 2019 580,000 shares of Dermapharm for the price of 30.00 Euros per share have been sold outside a trading venue.
06. Juni 2019 | Dermapharm Holding SE acquires a stake in fitvia
Grünwald, June 06, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, via Dermapharm AG is expanding the group to include a majority stake in the area of healthy nutrition. Dermapharm concluded an agreement to acquire an interest in fitvia GmbH, headquartered in Wiesbaden, Germany, today. With closing of the transaction, Dermapharm AG is acquiring 70.00 percent of the shares in the company specialized in healthy nutrition. The purchase agreement is still subject to the approval of the antitrust authority. The Management Board expects the transaction to be completed in the third quarter of 2019.
June 4, 2019 | Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.77 per share
Management Board and Supervisory Board discharged by large majority
Fiscal year 2018 marked by introduction of self-developed products, further internationalization and successful acquisitions
Continuation of profitable growth course in 2019
May 21, 2019 | Dermapharm Holding SE: First quarter of 2019 characterized by profitable growth
Grünwald, May 21, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading producer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, published its report for the first three months of 2019 today, having increased its revenues by 19.0% to EUR 163.6 million (prior-year quarter: EUR 137.5 million). Earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off costs of EUR 2.9 million in connection with the acquisition of the Spanish company Euromed and one-off costs of EUR 0.1 million for consulting services in connection with further acquisition efforts, increased by 20.7% to EUR 43.7 million (prior-year quarter: EUR 36.2 million). The adjusted EBITDA margin was 26.7%, 0.4 percentage points above the margin of the previous year. Unadjusted EBITDA amounted to EUR 40.7 million while the unadjusted EBITDA margin was 24.9%.
April 26, 2019 | Dermapharm to expand capacities at its main production site in Brehna
» Topping out ceremony for new logistics center in Brehna near Leipzig
» Expansion of the production site by 12,400 m²
» Total investments for new construction of around EUR 11 million
» Commitment to Germany as a business location and creation of the logistical prerequisites for the continued growth of the Dermapharm Group
April 17, 2019 | Dermapharm confirms its profitable growth in 2018 and presents positive outlook for 2019
Grünwald, April 17, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, today published its complete Annual Report 2018, confirming the preliminary IFRS Group financial figures for the year and the positive business development with significant revenue growth and a further increase in profitability.
April 03, 2019 | Dermapharm continues its profitable growth in 2018
Corporate news
to the archive
Dermapharm continues its profitable growth in 2018
Group revenue of EUR 572 million in 2018 around 23% higher than the previous year
Adjusted EBITDA increases by approx. 27% compared to last ...
March 4, 2019 | Dermapharm Holding SE acquires stake in cannabis producer for pharmaceutical applications
Corporate news
to the archive
Dermapharm Holding SE acquires stake in cannabis producer for pharmaceutical applications
Grünwald, March 4, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded ...
February 21, 2019 | Dermapharm continues to drive development of new products
Grünwald, February 21, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany, has launched the products Azedil® and Momekort® in Germany just in time for the hay fever season. In addition, the patented medical product bite away® from the 2018 Hyperthermia range has performed well in all sales channels.
January 23, 2019 | Dermapharm continues expansion course
Grünwald, January 23, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, is continuing its expansion course at the beginning of the year. The acquisition of the Spanish company EUROMED S.A. was completed at the beginning of January 2019.
November 20, 2018 | Dermapharm Holding SE reports positive business development in the third quarter of 2018
Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE, comments: “In the first nine months of 2018, we continued our positive business development, including our successful admission to the Prime Standard of the Frankfurt Stock Exchange, the integration of recent acquisitions as well as the successful introduction of in-house developments.
November 18, 2018 | Dermapharm Holding SE: Signing of contract for the acquisition of EUROMED S.A.
Corporate News
to the archive
Dermapharm Holding SE: Signing of contract for the acquisition of EUROMED S.A.
Grünwald, November 18, 2018 - Dermapharm Holding SE (ISIN: DE000A2GS5D8), a leading manufacturer of ...
November 16, 2018 | Dermapharm takes legal action against approval of a competitor product
Corporate news
to the archive
Dermapharm takes legal action against approval of a competitor product
Grünwald, November 16, 2018 - Dermapharm Holding SE (WKN A2GS5D, ISIN DE000A2GS5D8), a leading manufacturer of ...
September 12, 2018 | Dermapharm Holding SE publishes report for first half of 2018
Corporate news to the archive
Dermapharm Holding SE publishes report for first half of 2018
Group revenues increased by 19.7% to EUR 280.3 million
Adjusted EBITDA rose by 29.9% to EUR 70.9 million; EBITDA margin ...
August 21, 2018 | Dermapharm continues profitable growth in first half of 2018
Corporate news
to the archive
Dermapharm continues profitable growth in first half of 2018
Group revenues increased by around 20% from last year to EUR 280.3 million
Adjusted EBITDA increased by around 30% over ...
June 26, 2018 | Dermapharm Holding SE: First Annual General Meeting after successful IPO
Corporate news to the archive
Dermapharm Holding SE: First Annual General Meeting after successful IPO
Grünwald, June 26, 2018 – Dermapharm Holding SE (WKN A2GS5D, ISIN (DE000A2GS5D8), a leading producer of ...
May 18, 2018 | Dermapharm Holding SE publishes Q1 2018 report
Corporate news to the archive
Dermapharm Holding SE publishes Q1 2018 report
Revenues increased by 16.4% to EUR 137.5 million
Adjusted EBITDA increased by 25.3% to EUR 36.2 million, EBITDA margin improved to ...
April 27, 2018 | Dermapharm plans further profitable growth in 2018
Corporate news to the archiv
Dermapharm plans further profitable growth in 2018
Sales and earnings growth in 2017 resulted from a successful strategy with a focus on select therapy fields
Both segments ...
9. April 2018 | Dermapharm continued profitable growth in 2017
Corporate news to the archive
Dermapharm continued profitable growth in 2017
Revenue in 2017 up 4.9% from last year to EUR 467 million
Adjusted EBITDA up 9.7% from last year to EUR 113 million » Adjusted EBITDA ...
February 8, 2018 | Dermapharm Holding SE sets offer price at EUR 28.00 per share
Corporate news
to the archive
Not for release, publication or distribution in the United States, Canada, Australia or Japan.
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, ...
January 26, 2018 | Dermapharm Holding SE sets price range at EUR 26.00 to EUR 30.00 per share for its IPO
Corporate news to the archive
Not for release, publication or distribution in the United States, Australia, Canada or Japan.
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, ...
January 15, 2018 | Dermapharm Holding SE plans initial public offering
Corporate news
to the archive
Not for release, publication or distribution in the United States, Canada, Australia or Japan.
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, ...